Novartis nabs first FDA nod in rare kidney disease

The latest stories trending on MedCity News.

Editor's Pick

Top Story Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels Novartis's Fabhalta is the first FDA-approved therapy for C3 glomerulopathy. But Apellis Pharmaceuticals' Empaveli has superior clinical data, and that drug has been submitted for FDA review in the same rare kidney disease as well as another one that does not yet have an approved therapy. Sponsored Why Your Patients Are Leaving and How to Stop It Presented by Greenway Health Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust. Learn more. Dr. Jesse Ehrenfeld, Immediate Past President of American Medical Association will be Speaking at INVEST 2025! Jesse will be part of the panel, "What are Health Systems' Strategic Priorities in the Post-Pandemic Era?", discussing how hospitals are navigating the new normal—whatever that may be. With the immediacy of the crisis behind us, how are health systems working toward the Quadruple Aim in healthcare? Learn from top industry leaders as they share their insights. Register For INVEST Chicago Now

Featured News

The Mental Health Crisis: Why Immediate and Affordable Care Needs to Become the Norm Our mental health system is not designed to treat people in crisis. Instead of being administered right away and effectively, it shoves patients through a maze of barriers. If we are serious about saving lives, then we must reconsider how mental health care is administered. How Are Hospitals Faring Financially in 2025? Hospitals started 2025 with a stable financial performance driven by strong patient volumes, but rising costs for drugs, supplies, and services continue to put major pressure on margins. Aledade, Humana Expand Value-Based Partnership to Support FQHCs and Rural Health Clinics An expanded partnership with Humana will help Aledade's FQHC and rural health clinic partners share savings in Medicare Advantage. The Broken Approach to Health Disparities State, federal, and academic initiatives have poured time and resources into understanding and addressing these gaps. So why haven't we made real, lasting progress?

Video   What Needs to Be Done to Bring Down Prescription Drug Costs? Abarca Chief Growth and Commercial Officer Javier Gonzalez explained how PBMs can adopt new specialty drug pricing models, as well as how they can develop digital programs that help tackle the obesity crisis.

Sponsored How PDPM Optimization Improves Facility Financial Performance Presented by Medrina Transitioning to PDPM models significantly shifted the healthcare industry. By replacing the RUG system, healthcare providers cut waste and more accurately reflect the care each patient received. Learn More

Resources

Debunked Episode 13: Will the Real AI Please Stand Up? The latest episode of Debunked, with MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, talked about the many iterations of AI, NIH funding cuts, and a deal to sell Walgreens. Watch Now!

MedCity News • PO Box 901 • New York, NY unsubscribe